NCT07454226 2026-04-16
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting
Clinical Trials
18 trialsNCT07192237 2026-04-15
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07495631 2026-03-27
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting
NCT07476729 2026-03-17
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Charite University, Berlin, Germany
Phase 3 Not yet recruiting
NCT07178912 2026-03-09
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07223190 2026-03-04
AUDAX
Amgen
Phase 3 Not yet recruiting
NCT07443592 2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA Not yet recruiting
NCT06991920 2026-02-11
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting
NCT07313852 2026-02-04
A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Not yet recruiting
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT07283640 2025-12-22
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07297914 2025-12-22
FORUM2
Bambino Gesù Hospital and Research Institute
Phase 2/3 Not yet recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT06930105 2025-08-06
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06836973 2025-03-25
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Da, Yuwei, M.D.
Phase 2/3 Not yet recruiting
NCT06763302 2025-01-08
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The Children's Hospital of Zhejiang University School of Medicine
Phase NA Not yet recruiting
NCT06649422 2024-10-18
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
Shandong University
Not yet recruiting
NCT06075238 2023-10-10
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
Sichuan University
Phase 2 Not yet recruiting